Important Safety Information:  

GlucaGen^® has little or no effect if you are fasting, or if you are suffering from adrenal insufficiency, chronic hypoglycemia or alcohol induced hypoglycemia.  Nausea and vomiting may occur especially with doses above 1 mg.  Allergic reactions, including generalized rash, may occur. Do not use GlucaGen^® if you are allergic to glucagon or to one of the inactive ingredients in GlucaGen^®.  Hypoglycemia may occur again following glucagon treatment.  Warning:   The person may be in a coma from severe hyperglycemia (high blood sugar) rather than hypoglycemia (low blood sugar).  In such a case, the person will not respond to glucagon and will require immediate medical attention.

Please click here for GlucaGen^® HypoKit Prescribing Information

LEVEMIR^®

Indications and Usage:  Levemir ® (insulin detemir [rDNA] injection) is a man-made long-acting insulin that is used to control high blood sugar in adults and children with diabetes mellitus.

Important Safety Information:  Check your blood sugar levels. Ask your health care provider what your blood sugars should be and when you should check your blood sugar levels. Alcohol, including beer and wine, may affect your blood sugar when you take Levemir®.
Do not change the type of insulin you use unless told to do so by your health care provider. The amount of insulin you take as well as the best time for you to take your insulin may need to change if you take a different type of insulin.
Never mix Levemir® with other insulin products or use in an insulin pump.
Do not take Levemir® if your blood sugar is too low (hypoglycemia) or if you are allergic to anything in Levemir®.  If you take too much Levemir® your blood sugar may fall too low.
Tell your health care provider about all medicines you take and all of your medical conditions, including if you are pregnant or breastfeeding. Your Levemir® dose may change if you take other medicines.
The most common side effect of insulin therapy, including Levemir® is low blood sugar (hypoglycemia). Other possible side effects include reactions at the injection site (like redness, swelling and itching), and allergic reactions. Get medical help right away if you experience signs of serious allergic reaction such as body rash, trouble with your breathing, fast heartbeat, or sweating. Ask your doctor or pharmacist for further information.

Please click here for Levemir® Prescribing Information

Indications and Usage: NovoLog (R) is a man-made insulin that is used to control high blood sugar in adults and children with diabetes mellitus.

Important Safety Information: NovoLog (R) is a fast-acting insulin. You should eat a meal within 5 to 10 minutes after using NovoLog (R) to avoid low blood sugar. Do not inject NovoLog (R) if you do not plan to eat right after using NovoLog (R) . Check your blood sugar levels. Ask your healthcare provider what your blood sugars should be and when you should check your blood sugar levels. Alcohol, including beer and wine, may affect your blood sugar when you take NovoLog (R) .
Do not change the type of insulin you use unless told to do so by your healthcare provider. The amount of insulin you take as well as the best time for you to take it may need to change if you take a different type of insulin.
Do not mix NovoLog (R) with any other insulins when used in a pump or with any insulins other than NPH when used with injections by syringe.
Do not take NovoLog (R) if your blood sugar is too low (hypoglycemia) or if you are allergic to anything in NovoLog (R).  If you take too much NovoLog (R) your blood sugar may fall too low.
Tell your healthcare provider about all medicines you take and all of your medical conditions, including if you are pregnant or breastfeeding. Your NovoLog(R) dose may change if you take other medicines.
The most common side effect of insulin therapy, including NovoLog(R) is low blood sugar (hypoglycemia). Other possible side effects include reactions at the injection site (like redness, swelling and itching), and allergic reactions. Get medical help right away if you experience signs of serious allergic reaction, such as body rash, trouble with your breathing, fast heartbeat, or sweating. Ask your doctor or pharmacist for further information.

Please click here for NovoLog® Prescribing Information

NOVOLOG^® MIX 70/30

Indications and Usage: NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) is a man-made insulin that is used to control high blood sugar in adults with diabetes mellitus.

Important Safety Information: NovoLog® Mix 70/30 is a pre-mixed insulin. You should eat a meal within 15 minutes after using NovoLog® Mix 70/30 to avoid low blood sugar. Do not inject NovoLog® Mix 70/30 if you are not planning to eat within 15 minutes.  Check your blood glucose regularly. Ask your health care provider what your blood sugars should be and when you should check your blood sugar levels. Alcohol, including beer and wine, may affect your blood sugar when you take NovoLog® Mix 70/30.
Do not change the type of insulin you use unless told to do so by your health care provider. The amount of insulin you take as well as the best time for you to take your insulin may need to change if you take a different type of insulin.
Never mix NovoLog® Mix 70/30 with other insulin products or use it in an insulin pump.

Do not use NovoLog Mix 70/30 if your blood glucose is too low (hypoglycemia) or if you are allergic to anything in NovoLog® Mix 70/30.  If you take too much NovoLog® Mix 70/30 your blood sugar may fall too low.
Tell your health care provider about all medicines you take and all of your medical conditions, including if you are pregnant or breastfeeding. Your NovoLog® Mix 70/30 dose may change if you take other medicines.
 The most common side effect of insulin therapy, including NovoLog® Mix 70/30 is low blood sugar (hypoglycemia). Other possible side effects include reactions at the injection site (like redness, swelling and itching), and allergic reactions. Get medical help right away if you experience signs of serious allergic reaction such as body rash, trouble with your breathing, fast heartbeat, or sweating. Ask your doctor or pharmacist for further information.

Please click here for NovoLog^® Mix 70/30 Prescribing Information

PRANDIN^®

INDICATION AND USAGE
Prandin® (repaglinide) tablets are used in addition to diet and exercise to control blood sugar levels in adults with type 2 diabetes.

IMPORTANT SAFETY INFORMATION
Do not take Prandin® if you have diabetic ketoacidosis  (a complication of diabetes resulting in a buildup of ketones [a by-product of fat breakdown] in the body) with or without coma, type 1 diabetes or are allergic to Prandin® or any of its ingredients. Prandin® should not be used  in combination with NPH insulin. As with all blood glucose-lowering drugs, hypoglycemia (low blood sugar) is possible in people taking Prandin®. Mild to moderate hypoglycemia occurred in 16% of patients taking Prandin® alone.  Certain combinations of prescription medications may increase the chance of hypoglycemia and should be avoided when taking Prandin® (e.g. gemfibrozil and itraconazole). Therefore, it is important to tell your health care provider about all medications you take. 

In one-year clinical studies in patients taking only Prandin®, the most common side effects leading to discontinuation of Prandin® were hyperglycemia (high blood sugar), hypoglycemia, and related symptoms. The most common other side effects were cold- and flu-like symptoms, headache, nausea, diarrhea, joint ache, and back pain. In trials comparing Prandin® to another class of diabetes medications called sulfonylureas, serious heart-related side effects including ischemia (decreased blood blow to the heart), were higher with Prandin® (4% compared to 3%). In 1 year long controlled studies, treatment with Prandin® was not associated with an increased risk of death when compared to other diabetes medicines taken by mouth.

In clinical studies comparing Prandin® to another class of diabetes medications called thiazolidinedione (TZD), hypoglycemia occurred in 7% of patients taking both drugs, 7% of patients taking only Prandin®, and 2% of patients taking only TZD. When adjusted for dropout rates, the percentage of patient having fluid retention in the extremities per 24 weeks of treatment was 5% for patients taking both Prandin® and a TZD and 4% for patients taking only a TZD. No fluid retention in the extremities was reported in patients taking Prandin®. Two patients, both with a history of heart blood vessel disease, reported fluid retention with heart failure; no cases with patients taking either drug alone were reported. The average change in weight in patients taking Prandin® and a TZD was +4.9 kg.  

Please click here for Prandin® Prescribing Information